Core Insights - Cadrenal Therapeutics, Inc. has acquired the assets of eXIthera Pharmaceuticals, enhancing its pipeline with investigational intravenous and oral Factor XIa inhibitors, targeting the $38 billion global anticoagulation market [1][2][6] Company Overview - Cadrenal Therapeutics is focused on developing transformative therapeutics to address gaps in anticoagulation therapy, with its lead product being tecarfarin, a novel oral Vitamin K antagonist [7][10] Acquisition Details - The acquisition includes eXIthera's lead asset, frunexian, a Phase 2-ready intravenous Factor XIa inhibitor, and EP-7327, an oral Factor XIa inhibitor for major thrombotic conditions [2][6] - eXIthera will receive milestone payments up to $15 million based on future clinical and regulatory milestones, along with royalties on global sales of the acquired assets [6] Strategic Positioning - The acquisition positions Cadrenal as the only company developing both a novel vitamin K antagonist and Factor XIa inhibitors, aiming to fill critical gaps in current antithrombotic treatments [3][4] - Cadrenal plans to conduct trials for tecarfarin in patients with end-stage kidney disease transitioning to dialysis, and is strategically positioned to deliver differentiated therapeutics for cardiovascular thrombotic risk [4][11] Market Potential - The global anticoagulation market is valued at $38 billion, with the newly acquired assets addressing large and underserved segments [1][8]